Panel Biotech Growth Showcase Stage track
Why a Robust Clinical Strategy is Your Key to Growth-Stage Investment
Mon, Nov 16, 2026 · 4:30–5:00 PM GMT Old Billingsgate
About this session
In today's competitive life sciences funding environment, a compelling scientific hypothesis is no longer enough to secure growth-stage investment. Investors are increasingly scrutinizing clinical development strategies, demanding clear evidence of thoughtful trial design, realistic timelines, and capital-efficient pathways to value-creating milestones. This panel explores why a robust clinical strategy has become the critical differentiator between companies that successfully raise Series B+ rounds and those that stall out.
